Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer

ELISABETTA PIETRI, ILARIA MASSA, SARA BRAVACCINI, SARA RAVAIOU, MARIA MADDALENA TUMEDEI, ELISABETTA PETRACCI, CATERINA DONATI, ALESSIO SCHIRONE, FEDERICO PIACENTINI, LORENZO GIANNI, MARIO NICOLINI, ENRICO CAMPANDELI, ALESSANDRA GENNARI, ALESSANDRO SABA, BEATRICE CAMPI, LINDA VALMORRI, DANIELE ANDREIS, FRANCESCO FABBRI, DINO AMADORI, ANDREA ROCCA

aDepartment of Medical Oncology, bUnit of Biostatistics and Clinical Trials, cBiosciences Laboratory, and dOncology Pharmacy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; eDivision of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Modena, Italy; fDepartment of Oncology, Infermi Hospital, Rimini, Italy; gOncology Day Hospital Unit, Cervesi Hospital, Cattolica, Italy; hOncology Unit, Faenza Hospital, Faenza, Italy; iMedical Oncology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy; jDepartment of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy

TRIAL INFORMATION

- ClinicalTrials.gov Identifier: NCT02000375
- Sponsor(s): None
- Principal Investigator: Elisabetta Pietri
- IRB Approved: Yes

LESIONS LEARNED

- The androgen receptor (AR) is present in most breast cancers (BC), but its exploitation as a therapeutic target has been limited.
- This study explored the activity of dehydroepiandrosterone (DHEA), a precursor being transformed into androgens within BC cells, in combination with an aromatase inhibitor (to block DHEA conversion into estrogens), in a two-stage phase II study in patients with AR-positive/estrogen receptor-positive/human epidermal growth receptor 2-negative metastatic BC.
- Although well tolerated, only 1 of 12 patients obtained a prolonged clinical benefit, and the study was closed after its first stage for poor activity.

ABSTRACT

Background. Androgen receptors (AR) are expressed in most breast cancers, and AR-agonists have some activity in these neoplasms. We investigated the safety and activity of the androgen precursor dehydroepiandrosterone (DHEA) in combination with an aromatase inhibitor (AI) in patients with AR-positive metastatic breast cancer (MBC).

Methods. A two-stage phase II study was conducted in two patient cohorts, one with estrogen receptor (ER)-positive (resistant to AIs) and the other with triple-negative MBC. DHEA 100 mg/day was administered orally. The combination with an AI aimed to prevent the conversion of DHEA into estrogens. The main endpoint was the clinical benefit rate. The triple-negative cohort was closed early.

Results. Twelve patients with ER-positive MBC were enrolled. DHEA-related adverse events, reported in four patients, included grade 2 fatigue, erythema, and transaminitis, and grade 1 drowsiness and musculoskeletal pain. Clinical benefit was observed in one patient with ER-positive disease whose tumor had AR gene amplification. There was wide inter- and intra-patient variation in serum levels of DHEA and its metabolites.

Conclusion. DHEA showed excellent safety but poor activity in MBC. Although dose and patient selection could be improved, high serum level variability may hamper further DHEA development in this setting.

DISCUSSION

Androgen receptors are commonly expressed in BC, but androgens have variable effects in different BC subtypes, and both AR-agonists and AR-antagonists have been studied as anticancer agents in these tumors.

This multicenter, single-arm, two-stage phase II study evaluated the safety and activity of the androgen precursor DHEA, 100 mg/day orally continuously, in combination with...
an AI to prevent its transformation into estrogens, in two
cohorts of patients with AR-positive metastatic BC: one
with ER-positive/human epidermal growth factor receptor
2 (HER2)-negative and one with triple-negative disease.

Patients were postmenopausal and, when ER-positive,
had documented resistance to both nonsteroidal and ste-
roidal AIs. The primary endpoints were safety and activity
(clinical benefit rate: proportion of patients with stable dis-
ease or objective response after 16 weeks).

From November 2013 to July 2015, 12 patients were
enrolled in the ER-positive and 6 in the triple-negative
cohort; the last closed early, due to emerging preclinical
evidence of tumor stimulation by androgens.

In the ER-positive cohort, the median age was 74 years,
Eastern Cooperative Oncology Group (ECOG) performance sta-
tus 0–2; nine patients had visceral metastases, five were pre-
treated with 1–2 lines of chemotherapy and all with 1–4 lines
of endocrine therapy for advanced disease. The median dura-
tion of treatment was 71 days (range 55–697). Seven patients
showed progressive disease (PD) at 8 weeks, four had stable
disease (SD) at 8 weeks and PD at 16 weeks, and one had SD
lasting >16 weeks (692 days). Median time to progression
(TTP) was 63 days (95% confidence interval [CI] 57–126) and
median overall survival (OS) 559 days (95% CI 134–not
reached; Fig. 1). The study closed after the first stage for poor
activity. All patients in the triple-negative cohort had PD.

Toxicities deemed to be related to DHEA were (worst
grades) G2 fatigue, facial erythema, and increase in trans-
aminas (the last required temporary treatment interrup-
tion) and G1 sleepiness and joint/muscular pain. Other
toxicities, attributable to AIs or the underlying disease,
included four serious adverse events: uncontrolled pain,
trauma, seizure, and constipation, and all but the last were
considered not treatment related.

There was wide intra- and inter-patient variability in
DHEA serum levels.

The patient who experienced prolonged SD was the
only one showing AR gene amplification.

The combination DHEA-AI was well tolerated but poorly
active in ER-positive metastatic BC. Although dose and
patient selection could be further studied, variability in
serum levels and in tumor intracrinology (the intracellular
formation of sex steroids from DHEA) may hamper further
DHEA development in BC.

**Figure 1.** (A) Time to progression and (B) overall survival of the estrogen receptor-positive cohort.

Abbreviations: OS, overall survival; TTP, time to progression.

| **Trial Information** | **Breast cancer** |
|----------------------|------------------|
| **Disease**          | Metastatic/advanced |
| **Stage of Disease/Treatment** | More than two prior regimens |
| **Prior Therapy**    | Phase II |
| **Type of Study – 1** | Single arm |
| **Type of Study – 2** | Clinical benefit rate (proportion of patients with stable disease or objective response after 16 weeks of therapy) |
| **Primary Endpoint** | Safety |

© AlphaMed Press 2018
Secondary Endpoint | Toxicity
--- | ---
Secondary Endpoint | Overall response rate
Secondary Endpoint | Time to progression
Secondary Endpoint | Overall survival
Secondary Endpoint | Correlative endpoint

Additional Details of Endpoints or Study Design

Study design: Simon two-stage design with 10% alpha and beta errors. Assuming an acceptable minimum clinical benefit of 10% and a desirable clinical benefit of 30%, 12 patients were required per cohort in the first stage, with the intent to continue recruitment up to a total of 35 patients per cohort if the number of patients achieving clinical benefit was ≥ 2 at the first stage, and considering the combination active if the total number of patients achieving clinical benefit was ≥ 6 in the entire cohort. Descriptive statistics are reported as frequencies and percentages for categorical variables and as median and range for continuous variables. Boxplots are used to represent serum levels of DHEA and glucuronidated metabolites at different time points, and the Friedman nonparametric repeated measure analysis of variance was used to test differences in their distribution over time. TTP and OS curves were estimated using the Kaplan-Meier method.

Correlative endpoints: (a) On formalin fixed, paraffin-embedded tumor samples, we assessed AR expression (AR Cell Marque antibody, clone SP107; Ventana Medical Systems, Oro Valley, AZ) and phosphorylation (Novus Biologicals pSer 650 NBP1-60769 and pSer 210-213 NB 100-56603 antibodies; Novus Biologicals, Littleton, CO) by immunohistochemistry and AR gene copy number by fluorescence in situ hybridization using Vysis LSI Androgen Receptor Gene (Xq12) SpectrumOrange Probe kit (Abbott Molecular, Des Plaines, IL); (b) measurement of serum levels of DHEA and of its glucuronidated metabolites androstane-3alpha,17beta-diol-3-glucuronide (3-diol-3G), androstane-3alpha,17beta-diol-17glucuronide (3-diol-17G), and androsterone glucuronide (ADT-G) [44].

Investigator’s Analysis

Level of activity did not meet planned endpoint

| Drug Information |  |
| --- | --- |
| **Drug 1** |  |
| Generic/Working Name | Dehydroepiandrosterone |
| Trade Name | Company Name |
| Drug Type | Androgen precursor |
| Drug Class | Androgen receptor |
| Dose | 100 mg flat dose |
| Route | p.o. |
| Schedule of Administration | 100 mg/day continuously |
| **Drug 2** |  |
| Generic/Working Name | Anastrozole or exemestane or letrozole |
| Trade Name | Company Name |
| Drug Type | Aromatase inhibitor |
| Drug Class | Estrogen receptor |
| Dose | 1, 25, 2.5 (respectively) mg flat dose |
| Route | p.o. |
| Schedule of Administration | 1 tablet/day continuously |

| Patient Characteristics |  |
| --- | --- |
| Number of Patients, Male | 0 |
| Number of Patients, Female | 18 |
| Stage | Stage IV breast cancer |
| Age | Median (range): 74 (50–90) |
| Number of Prior Systemic Therapies | Median (range): 2 (1–4) |
| Performance Status: ECOG | 0 — 14 |
| | 1 — 3 |
| | 2 — 1 |
| | 3 — |
| | Unknown — |
| Cancer Types or Histologic Subtypes | Estrogen receptor-positive, HER2-negative breast cancer, 12 |
| | Triple-negative breast cancer, 6 |
### Primary Assessment Method

| Title                                      | Estrogen receptor-positive, HER2-negative cohort |
|--------------------------------------------|--------------------------------------------------|
| Number of Patients Screened               | 13                                               |
| Number of Patients Enrolled               | 12                                               |
| Number of Patients Evaluable for Toxicity | 12                                               |
| Number of Patients Evaluated for Efficacy | 12                                               |
| Evaluation Method                          | RECIST 1.1                                       |
| Response Assessment CR                     | \(n = 0\) (0%)                                   |
| Response Assessment PR                     | \(n = 0\) (0%)                                   |
| Response Assessment SD                     | \(n = 5\) (42%)                                  |
| Response Assessment PD                     | \(n = 7\) (58%)                                  |
| (Median) Duration Assessments TTP         | 63 days, CI: 57–126                              |
| (Median) Duration Assessments OS          | 559 days, CI: 134–not reached [NR]               |
| (Median) Duration Assessments Duration of Treatment | 71 days                       |

**Outcome Notes**

Clinical benefit rate (CR or PR or SD at week 16): one patient (8%). Enrollment in the triple-negative cohort was closed in advance because of both slow recruitment and preclinical data suggesting that AR may drive tumor progression in some subtypes of triple-negative breast cancer.

### Adverse Events

| All Cycles | Name                          | NC/NA | 1     | 2     | 3     | 4     | 5     | All grades |
|------------|-------------------------------|-------|-------|-------|-------|-------|-------|------------|
| All Cycles | Gastrointestinal pain        | 94%   | 6%    | 0%    | 0%    | 0%    | 0%    | 6%         |
| All Cycles | Fatigue                       | 77%   | 17%   | 6%    | 0%    | 0%    | 0%    | 23%        |
| All Cycles | Anorexia                      | 89%   | 11%   | 0%    | 0%    | 0%    | 0%    | 11%        |
| All Cycles | Dysphagia                     | 94%   | 6%    | 0%    | 0%    | 0%    | 0%    | 6%         |
| All Cycles | Dyspepsia                     | 88%   | 6%    | 6%    | 0%    | 0%    | 0%    | 12%        |
| All Cycles | Nausea                        | 83%   | 17%   | 0%    | 0%    | 0%    | 0%    | 17%        |
| All Cycles | Vomiting                      | 89%   | 11%   | 0%    | 0%    | 0%    | 0%    | 11%        |
| All Cycles | Constipation                  | 94%   | 6%    | 0%    | 0%    | 0%    | 0%    | 6%         |
| All Cycles | Diarrhea                      | 89%   | 11%   | 0%    | 0%    | 0%    | 0%    | 11%        |
| All Cycles | Enterocolitis infectious      | 94%   | 0%    | 6%    | 0%    | 0%    | 0%    | 6%         |
| All Cycles | Dyspnea                       | 89%   | 11%   | 0%    | 0%    | 0%    | 0%    | 11%        |
| All Cycles | Cough                         | 88%   | 6%    | 6%    | 0%    | 0%    | 0%    | 12%        |
Androgen receptors (AR) are expressed in 60%–90% of breast cancers (BC), mainly in estrogen receptor (ER)-positive tumors [1, 2]. Androgens have variable effects in different BC models [3–5]: often antiproliferative [6–13], mainly in ER-positive tumors; sometimes pro-proliferative [14–18], mainly in triple-negative and human epidermal growth factor receptor 2 (HER2)-positive/ER-negative tumors. Both AR-agonists [19–22] and AR-antagonists are being studied as antitumor agents in BC [23–27]. Dehydroepiandrosterone (DHEA) is a steroid produced mainly by the adrenal cortex and transformed into sex hormones (androgens and estrogens) within peripheral target tissues [28–33]. The action of sex steroids is confined within the cells in which they are synthesized (a process called “intracrinology”), with little or no release into the extracellular spaces or the general circulation. This process also occurs within BC cells, and there is preclinical evidence of antitumor activity of DHEA in BC [34–40]. The administration of an aromatase inhibitor (AI) prevents the conversion of DHEA into estrogens and favors its conversion into androgens.

To investigate the role of androgens in BC, avoiding the virilizing effects of available androgenic agents, we conducted a two-stage, phase II, prospective clinical study to evaluate the safety and activity of DHEA 100 mg/day in combination with an AI (anastrozole 1 mg/day, letrozole 2.5 mg/day, or exemestane 25 mg/day) in two cohorts of patients with AR-positive metastatic breast cancer: one with ER-positive/HER2-negative (ER-positive cohort) and one with triple-negative (TN cohort) disease.

The DHEA dosage was chosen based on the reported saturation of the enzymatic systems that transform DHEA into sex steroids, occurring at serum levels of about 7 ng/mL [41, 42], and to the reported serum DHEA levels of about 7 ng/mL achieved after oral administration of DHEA 100 mg daily for 6 months [43]. DHEA was produced by the Oncology Pharmacy Laboratory of our institute, whereas AIs were purchased commercially. Serum levels of DHEA and its glucuronidated metabolites were measured by liquid chromatography-tandem mass spectrometry [44]. The expression of AR and of its main phosphorylated forms (AR 650 and AR 210-213) was assessed by immunohistochemistry and AR gene amplification by fluorescence in situ hybridization.

Patients characteristics are reported in the designated Table. All patients in the ER-positive cohort had developed resistance to both nonsteroidal and steroidal AIs. Seven patients had received an AI as their last line of treatment before entering the trial and, after progressing on the AI, had continued the same AI but with the addition of DHEA. Conversely, five patients received DHEA in combination with an AI to which they had developed resistance in the past, but which was not the last line of therapy they received before entering this trial.

Toxicity is reported in the “adverse events” table. The four serious adverse events reported were not attributed to DHEA. Two patients died within 30 days of the end of therapy, one after 8 days and one after 21 days, all due to tumor progression. No virilizing effects were registered.

| Name                                      | Grade | Attribution  |
|--------------------------------------------|-------|--------------|
| Uncontrolled pain                         | 2     | Unrelated    |
| Cranial trauma                            | 2     | Unrelated    |
| Seizures                                   | 2     | Unrelated    |
| Constipation and abdominal pain            | 2     | Unlikely     |

Serious Adverse Events Table

| Name                                      | Grade | Attribution  |
|--------------------------------------------|-------|--------------|
| Uncontrolled pain                         | 2     | Unrelated    |
| Cranial trauma                            | 2     | Unrelated    |
| Seizures                                   | 2     | Unrelated    |
| Constipation and abdominal pain            | 2     | Unlikely     |

ASSESSMENT, ANALYSIS, AND DISCUSSION

Completion

- Study completed
- Level of activity did not meet planned endpoint

© AlphaMed Press 2018
Only one patient had clinical benefit, with stable disease (SD) for almost 99 weeks. She had previously received letrozole for 4 years for a regional relapse and then tamoxifen for 8 months upon progression. Following further progression, she was enrolled in the trial and received letrozole + DHEA.

The three patients whose tumors showed lower AR expression levels (<50% of positive cells and H-score < 100) had disease progression (PD) after 8 weeks, whereas five of the seven patients with higher AR expression showed SD at this time. AR phosphorylation and AR gene copy number were available for 10 patients (Table 2). Remarkably, the patient with clinical benefit was the only one whose tumor harbored an AR gene amplification, with AR gene clusters observed in 20% of tumor cells. All tumor samples showed AR phosphorylation at serine 650 (p650) in variable amounts and at different locations (cytoplasm or nucleus). The two patients with lower p650 H-scores (<100) had PD at 8 weeks, whereas the eight patients with intermediate/high H-scores, five had SD and three had disease progression at 8 weeks. The patient who experienced prolonged SD had a nuclear expression of p650, whereas in most cases p650 was found in the cytoplasm. AR phosphorylation at serine 210-213 was present, mainly in the nucleus, in only three patients, one of whom was the patient with prolonged SD.

Serum levels of DHEA and its glucurononidated metabolites androstatane-3alpha,17beta-diol-3-glucuronide (3α-diol-3G), androstatane-3alpha,17beta-diol-17glucuronide (3α-diol-17G), and androgenone glucuronide (ADT-G) were measured at baseline, at 8 weeks, and at the end of treatment in 10 patients. DHEA was assessable at all three time-points in four patients, 3α-diol-3G in two patients, 3α-diol-17G in seven patients, and ADT-G in eight patients. There was wide intra- and interpatient variation in DHEA serum levels (Fig. 2), but no significant changes over time were observed, probably because of the small number of patients with all measurements ($p = .333$). Only one patient had DHEA values constantly above the target threshold of 7 ng/mL and progressed after 8 weeks. The patient with prolonged disease stabilization had a median DHEA serum level of 4.01 ng/mL. Among the glucurononidated metabolites (Fig. 3), median serum levels of 17α-diol-17G and ADT-G showed significant changes over time ($p = .020$ and $p = .007$, respectively, Friedman test). No clear pattern of metabolite levels emerged in relation to response to treatment at 8 weeks.

The poor activity of DHEA in our study may partly be due to heavy pretreatment, which may have compromised hormone sensitivity. Variability in adrenal function [45], in DHEA disposition after oral administration especially in elderly patients [46–59], and in BC cells intracrinology may further be involved [60].

The AR gene amplification present in the only patient who showed a prolonged clinical benefit is intriguing, prompting to hypothesize the potential value of AR gene amplification as a predictive biomarker of response to androgenic treatments in breast cancer. However, the small number of patients involved in the study and the low rate of clinical benefit prevents any definitive conclusions from being drawn. Similarly, the role of phosphorylated AR remains to be ascertained.

**ACKNOWLEDGMENTS**

We thank Gráinne Tierney and Cristiana Verna for editorial assistance. This project was partially funded by the Italian Ministry of Health (project code GR-2009-1594885).

**DISCLOSURES**

Lorenzo Gianni: Pfizer, Novartis (C/A), Pfizer, Roche (Other: congress travel expenses); Alessandra Gennari: Novartis, Pfizer, Gentili, Eisai, Eli Lilly & Co. (C/A), Roche (RF). The other authors indicated no financial relationships.

(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (O) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board

**REFERENCES**

1. Collins LC, Cole KS, Marotti JD et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: Results from the Nurses’ Health Study. Mod Pathol 2011;24:924–931.
2. Vera-Badillo FE, Templeton AJ, de Gouveia P et al. Androgen receptor expression and outcomes in early breast cancer: A systematic review and meta-analysis. J Natl Cancer Inst 2014;106: djt319.
3. Labrie F, Simard J, de Launoit Y et al. Androgenic treatments in breast cancer. However, the small number of patients involved in the study and the low rate of clinical benefit prevents any definitive conclusions from being drawn. Similarly, the role of phosphorylated AR remains to be ascertained.

2. Vera-Badillo FE, Templeton AJ, de Gouveia P et al. Androgen receptor expression and outcomes in early breast cancer: A systematic review and meta-analysis. J Natl Cancer Inst 2014;106: djt319.
3. Labrie F, Simard J, de Launoit Y et al. Androgenic treatments in breast cancer. However, the small number of patients involved in the study and the low rate of clinical benefit prevents any definitive conclusions from being drawn. Similarly, the role of phosphorylated AR remains to be ascertained.

© AlphaMed Press 2018
estrogen receptor alpha. Cancer Res 1999;59: 4864–4869.

17. Cochrane DR, Bernales S, Jacobsen BM et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res 2014;16:87.

18. Barton VN, D’Amato NC, Gordon MA et al. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther 2015;14:769–778.

19. Gordan GS, Halden A, Horn Y et al. Calus-torone (7beta, 17alpha-dimethyltestosterone) as primary and secondary therapy of advanced breast cancer. Oncology 1973;28:138–146.

20. Goldenberg IS, Waters N, Ravdin RS et al. Androgenic therapy for advanced breast cancer in women. A report of the cooperative breast cancer group. JAMA 1973;223:1267–1268.

21. Coni C, Pagano M, Panebianco M et al. Therapeutic activity of testosterone in metastatic breast cancer. Anticancer Res 2014;34:1287–1290.

22. Glaser R, Dimitrakakis C. Testosterone and breast cancer prevention. Maturitas 2015;82: 291–295.

23. D’Amato NC, Gordon MA, Babbs B et al. Cooperative dynamics of AR and ER activity in breast cancer. Mol Cancer Res 2016;14: 1054–1067.

24. Krop I, Cortes J, Miller K et al. A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer. Cancer Res 2017;77(suppl 4):P4-22-08a.

25. Schwartzberg LS, Yardley DA, Elias AD et al. A phase I/Ib study of enzalutamide alone and in combination with endocrine therapies in women with advanced breast cancer. Clin Cancer Res 2017;23:4046–4054.

26. Krop I, Abraham V, Colleoni M et al. Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor-positive breast cancer. Cancer Res 2018;78(suppl 4): G54-07a.

27. Traina TA, Miller K, Yardley DA et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol 2018;36:884–890.

28. Labrie F, Luu-The V, Bélanger A et al. Is dehydroepiandrosterone a hormone? J Endocrinol 2005;187:169–196.

29. Labrie F, Luu-The V, Labrie C et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152–182.

30. Truich AM, Kang HP, Saad F et al. Dehydroepiandrosterone (DHEA)—A precursor steroid or an active hormone in human physiology. J Sex Med 2011;8:2960–2982.

31. Eirayah T, Sonbol MB, Wang Z et al. Clinical review: The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: A systematic review and meta-analysis. J Clin Endocrinol Metab 2014;99:3536–3542.

32. Rutkowski K, Sowa P, Rutkowska-Talipsa J et al. Dehydroepiandrosterone (DHEA): Hypes and hopes. Drugs 2014;74:1195–1207.

33. Prough R, Clark BJ, Klinge CM. Novel mech-anism for DHEA action. J Mol Endocrinol 2016;56:R139–155.

34. Shilikatis A, Green A, Punj V et al. Dehydro-epiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p53-independent mechanism. Breast Cancer Res 2005;7:R1132–1140.

35. Hakak R, Shaaf S, Jo CH et al. Dehydroepiandrosterone intake protects against 7,12-dimethylbenz(a)anthracene-induced mammary tumor development in the obese Zucker rat model. Oncol Rep 2010;24:357–362.

36. Schwartz AG, Pashko L, Whitcomb JM. Inhi-bition of tumor development by dehydroepiandrosterone and related steroids. Toxicol Pathol 1986;14:357–362.

37. Gordon GB, Shantz LM, Talalay P. Modul-ation of growth, differentiation and carcinogene-sis by dehydroepiandrosterone. Adv Enzyme Regul 1987:26:355–382.

38. U S, Yan X, Bélanger A et al. Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat. Breast Cancer Res Treat 1994;29:203–217.

39. Sandra N, Ester P, Marie-Agnès P et al. The DHEA metabolite 7β-hydroxy-epiandrosterone exerts anti-estrogenic effects on breast cancer cell lines. Steroids 2012;77:542–551.

40. Bocuzzi G, Di Monaco M, Brignardello E et al. Dehydroepiandrosterone antitumor action through androgen receptor in MCF-7 human breast cancer cell line. Anticancer Res 1993;13:2267–2272.

41. Labrie F. DHEA, important source of sex steroids in men and even more in women. Poten-tial remedi effects. Ann N Y Acad Sci 1995;774: 128–142.

42. Wolkowitz OM, Reus VI, Roberts E et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997;41: 311–318.

43. Bloch M, Melboom H, Ziai I et al. The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: A report of gender differences. Eur Neuropsychopharmacol 2013;23:910–918.

44. Christiansen JJ, Bruun JM, Christiansen JS et al. Long-term DHEA substitution in female adrenocortical failure, body composition, muscle function, and bone metabolism: A randomized trial. Eur J Intern Med 2011;165:293–300.

45. Genazzani AR, Stomati M, Valerino V et al. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric 2011;14:661–668.

46. Barry NN, McGuire JL, van Vollenhoven RF. Dehydroepiandrosterone in systemic lupus erythematosus: Relationship between dosage, serum levels, and clinical response. J Rheumatol 1998;25:2352–2356.

47. Labrie F, Cusan L, Gomez JL et al. Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. J Steroid Biochem Mol Biol 2008;110:1–9.

48. Labrie F, Bélanger A, Bélanger P et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 2006:99: 182–188.

49. Africander D, Storbeck KH. Steroid metabo-lism in breast cancer: Where are we and what are we missing? Mol Cell Endocrinol 2018;466:86–97.
Figure 2. Individual serum concentrations of dehydroepiandrosterone (DHEA) and metabolites in 10 patients from the estrogen receptor-positive cohort. The following are reported for each patient: Left panels: serum concentrations of DHEA, androstane-3α,17β-diol-3-glucuronide (3α-diol-3G), and androstane-3α,17β-diol-17β-glucuronide (3α-diol-17G) at different time points during treatment. Right panels: serum concentrations of androsterone glucuronide (ADT-G) at different time points during treatment. Solid line: DHEA levels; dotted line: 3α-diol-3G levels; dashed line: 3α-diol-17G levels; dash-dotted line: ADT-G levels. Abbreviations: Baseline, before starting treatment; C1D14, cycle 1 day 14; C2D1, cycle 2 day 1; EOT, end of treatment.
**Table 1. Patient and tumor characteristics**

| Variable                                      | Cohort 1 (n = 12), n (%) | Cohort 2 (n = 6), n (%) |
|-----------------------------------------------|--------------------------|-------------------------|
| Median age, years (range)                     | 74 (58–90)               | 76 (50–86)              |
| Performance status [ECOG]                     |                          |                         |
| 0                                             | 9 (75)                   | 5 (83)                  |
| 1                                             | 2 (17)                   | 1 (17)                  |
| 2                                             | 1 (8)                    | —                       |
| Hormone receptors<sup>a</sup>                 |                          |                         |
| Androgen-positive                             | 12                       | 6                       |
| Estrogen-positive                             | 12                       | —                       |
| Estrogen-negative                             |                          |                         |
| Progesterone-positive                         | 9 (75)                   | —                       |
| Progesterone-negative                         | 3 (25)                   | 6                       |
| Negative HER2 status<sup>a</sup>             | 12                       | 6                       |
| Number of metastatic sites                    |                          |                         |
| 1                                             | 2 (16.67)                | 1 (17)                  |
| 2                                             | 2 (16.67)                | 2 (33)                  |
| 3                                             | 6 (50.00)                | 2 (33)                  |
| 4                                             | 2 (16.67)                | 1 (17)                  |
| Sites of metastases                           |                          |                         |
| Soft tissues (only)                           | 2 (17)                   | 0                       |
| Bone (± soft tissue)                          | 1 (8)                    | 1 (17)                  |
| Viscera (± other)                             | 9 (75)                   | 5 (83)                  |
| Previous lines of hormone therapy for MBC     |                          |                         |
| 1                                             | 1 (8)                    | —                       |
| 2                                             | 6 (50)                   | —                       |
| 3                                             | 3 (25)                   | —                       |
| 4                                             | 2 (17)                   | —                       |
| Previous lines of chemotherapy for MBC        |                          |                         |
| 0                                             | 7 (58)                   | 1 (17)                  |
| 1                                             | 3 (25)                   | 1 (17)                  |
| 2                                             | 2 (17)                   | 2 (33)                  |
| 3                                             | —                        | 2 (33)                  |
| Chosen aromatase inhibitor                    |                          |                         |
| Exemestane                                    | 6 (50)                   | 4 (67)                  |
| Anastrozole                                   | 4 (33)                   | 2 (33)                  |
| Letrozole                                     | 2 (17)                   | —                       |
| Last line of therapy before enrollment into   |                          |                         |
| this clinical trial                           |                          |                         |
| Same AI, continued within this study          | 7 (58)                   | —                       |
| Other treatment                               | 5 (42)                   | —                       |

<sup>a</sup>Based on the most recent tumor biopsy performed (Cohort 1: six primary tumors and six metastases; Cohort 2: three primary tumors and three metastases).

Abbreviations: —, no data; AI, aromatase inhibitor; ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth receptor 2; MBC, metastatic breast cancer.
Figure 3. Boxplots of serum concentrations of DHEA and metabolites. Box and whisker plots, showing the median, interquartile range, and the highest and lowest values for each analyte at three time points (baseline, cycle 2 day 1, and end of treatment). Abbreviations: C2, cycle 2 day 1; DHEA, dehydroepiandrosterone; EOT, end of treatment.

Table 2. Androgen receptor expression, phosphorylation, and gene amplification

| Patient | Site                   | AR (nuclear) | AR FISH | AR p650 | AR p210-213 | Response at 8 weeks |
|---------|------------------------|--------------|---------|---------|-------------|---------------------|
| 1       | M (chest wall skin)    | 70 3 210 +   | 45 + -  | 2-3 135  | 10 + - 1    | 10 SD               |
| 2       | P                      | 90 3 270 -   | 90 - +  | 3 270    | 0           | PD                  |
| 3       | P                      | 90 3 270 -   | 80 + +  | 3 240    | 35 + + 1    | 35 SD               |
| 4       | P                      | 30 2 60 -    | 95 - +  | 3 285    | 0           | PD                  |
| 5       | P                      | 90 3 270 -   | 50 - +  | 2-3 150  | 30 + - 1    | 30 PD               |
| 6       | M (chest wall skin)    | 95 3 285 -   | 100 - + | 3 300    | 0           | SD                  |
| 7       | P (relapse)            | 85 3 255 -   | 90 - +  | 3 270    | 0           | SD                  |
| 8       | M (mediastinum)        | 80 3 240 -   | 90 - +  | 3 270    | 0           | SD                  |
| 9       | P                      | 25 2 50 -    | 70 + -  | 1 70     | 0           | PD                  |
| 10      | P                      | 30 3 90 -    | 30 + +  | 2 60     | 0           | PD                  |

Abbreviations: %, percentage of stained cells; AR, androgen receptor; AR FISH, AR gene amplification by fluorescence in situ hybridization; C, cytoplasm; H, H-score (= % * Int); Int, staining intensity; M, metastasis; N, nuclear; P, primary tumor; p650, phosphorylation at serine 650; p210-213, phosphorylation at serine 210-213; PD, progressive disease; SD, stable disease.